Clinical trials: Personalized Cancer Vaccine
Kidney Cancer
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer.
- Trial name
- NCT02950766
- Testing
- NeoVax, Ipilimumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patrick Ott, MD, PhD
Advanced Solid Tumor, Cancer
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
This is a prospective, single-center, open-label, real-world clinical study designed to evaluate the safety, efficacy, and immunogenicity of Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）in…
- Conditions
- Advanced Solid Tumor, Cancer, Malignant Solid Tumor
- Trial name
- ZSNeo-DC-RWS (NCT07752953)
- Testing
- Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ZSky Biotech Inc
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with…
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- PANDA-VAC (NCT04266730)
- Testing
- PANDA-VAC, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer Female
Personalized Vaccine for Cancer Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNTC)] and other tumors such as melanoma…
- Trial name
- NCT04879888
- Testing
- Peptide pulsed Dendritic cell
- Where
- Colombia
- Volunteers
- 9 people
- Sponsor
- Universidad Nacional de Colombia
Solid Tumors, Advanced Cancer
Personalized Neoantigen Peptide Vaccines for Solid Tumors
This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors.
- Conditions
- Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy
- Trial name
- NCT07002203
- Testing
- Personalized Neoantigen Peptide Vaccine
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Seqker Biosciences, Inc.
Advanced Malignant Solid Tumor
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
This research study is evaluating a new type of personalized neoantigen cancer vaccine（iNeo-Vac-P01）combined with anti-PD-1 antibody and radiofrequency ablation as a possible treatment for patients with advanced solid tumors.
- Trial name
- NCT04864379
- Testing
- iNeo-Vac-P01, GM-CSF, PD-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Glioblastoma
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
This is a multicenter, open-label, randomized Phase II clinical study designed to evaluate the efficacy and safety of a personalized dendritic cell (DC) vaccine, ZSNeo-DC1.1, in combination with temozolomide (TMZ) as adjuvant…
- Trial name
- NCT07365280
- Testing
- Personalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ)
- Volunteers
- 78 people
- Sponsor
- ZSky Biotech Inc
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University